DLA Piper advised Iovance, and Latham & Watkins advised the underwriters.Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) announced the pricing of an underwritten public offering of 20,000,000 shares of…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
